Immunotherapies and/or FGFR4 inhibitors for HCC patients in C2, CTNNB1-targeted therapies for those in C3, and therapies targeting the molecules Wnt–β-catenin pathway and/or the PI3K pathway for those in C1, may be potential therapeutic strategies that warrant further investigation. The gene discussed is FGFR4; the disease is hepatocellular carcinoma.